Don’t worry if you never heard of Dr. J. Joseph Kim. Most investors haven’t-at least not yet. He’s the CEO of an early-stage biotech firm that has developed a truly novel product for one of the nation’s major medical markets -- vaccines. It’s a $30 billion a year business in just the U.S. alone.
